Canadian company Valeant Pharmaceuticals International has completed the sale of all outstanding equity interests in its subsidiary Dendreon Pharmaceuticals to the Sanpower Group for $819.9m. 

Under the deal, Valeant Pharmaceuticals will use net proceeds from the sale to permanently repay term loan debt under its senior credit facility. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Upon closing the transaction, the company expects to pay down $5bn in debt from the sale proceeds and free cash-flow within 18 months after next month. 

Valeant Pharmaceuticals International chairman and chief executive officer Joseph Papa said: "We continue to deliver on our commitments to reduce debt and simplify our portfolio, while focusing resources on our core businesses.

"Proceeds from this sale along with the recently announced sale of the iNova business move us closer to paying down $5bn of debt from divestitures and free cash-flow."

“The proceeds from this sale along with the recently announced sale of the iNova business move us closer to paying down $5bn of debt from divestitures and free cash-flow, and we are confident we will meet and potentially exceed this commitment.”

See Also:

As estimated by Valeant, expected revenue and adjusted earnings before interest, tax, depreciation, and amortisation (EBITDA) (non-GAAP) from the Dendreon business in the second half of this year would have been $170m and $65m respectively. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In January, Valeant Pharmaceuticals’ affiliate entered a definitive agreement to sell the outstanding equity interests in Dendreon. 

The first and only commercialised product of Dendreon Pharmaceuticals is Provenge, which is an autologous cellular immunotherapy (vaccine) for prostate cancer treatment. 

Provenge received approval from the US Food and Drug Administration (FDA) in April 2010.